HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company, announced the pricing of a public offering providing for aggregate gross proceeds of approximately $10.0 million, before underwriting discounts and offering expenses, subject to customary closing conditions.
The offering consists of shares of common stock offered at a public offering price per share as disclosed in the final prospectus. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
Net proceeds from the offering are expected to be used for working capital and general corporate purposes, including advancing the Company’s product development and commercialization initiatives.
The Benchmark Company, LLC acted as the sole book-running manager for the offering. Lucosky Brookman LLP served as counsel to HeartBeam, Inc. in connection with the transaction.
